GLOW counties to share approximately $ 3.25 million in cash for opioid crisis resolution | Local News
Attorney General to provide up to $ 1.5 billion to local communities to fight opioid crisis
NEW YORK – New York Attorney General Letitia James said today she will begin providing the first of $ 1.5 billion to fight the opioid epidemic. The funds – which will go to the 10 regions of the state – come from various settlements that James negotiated following his lawsuit in March 2019 against the various manufacturers and distributors responsible for the opioid crisis.
James said the settlement included the following minimum and maximum amounts for counties in the GLOW region:
n County of Genesee: $ 597,359.78 and $ 1,043,594.62
n Livingston County: $ 570,600.77 and $ 996,846.31
n County of Orleans: $ 347,049.64 and $ 606,299.83
n Wyoming County: $ 346,041.37 and $ 604,538.38
James said the settlement total for the Southern Tier, which includes a regional share, is between $ 14,522,096.97 and $ 26,516,410.21.
The attorney general said the 2019 lawsuit was, at the time, the largest lawsuit in the country against various opioid manufacturers and distributors.
“These manufacturers and distributors were responsible for the massive marketing of opioids to physicians, hospitals, health systems and others, which has led to over-prescribing of drugs in New York and the rest of the country over the years. last two decades. “
The manufacturers named in Attorney General James’ complaint included Purdue Pharma and its affiliates, as well as members of the Sackler family (owners of Purdue) and the trusts they control; Janssen Pharmaceuticals and its subsidiaries (including its parent company Johnson & Johnson); Mallinckrodt LLC and its affiliates; Endo Health Solutions and its affiliates; Teva Pharmaceuticals USA, Inc. and its subsidiaries; and Allergan Finance, LLC and its affiliates. The distributors named in the complaint were McKesson Corporation, Cardinal Health Inc., Amerisource Bergen Drug Corporation and Rochester Drug Cooperative Inc.
Last month, a settlement was announced with Endo, which has already provided $ 50 million to New York State, Nassau and Suffolk counties to tackle the opioid crisis and remove the opioid maker from opioid trial underway in New York.
In addition, last month a settlement that raised more than $ 4.5 billion – of which at least $ 200 million will go to New York – from the Sackler family and the foundations they control, put The Sacklers’ ability to re-manufacture opioids ended, and the shutdown of Purdue Pharma was announced.
In July, an agreement with McKesson, Cardinal Health and Amerisource Bergen that will provide up to $ 1 billion to New York State to fight the opioid epidemic was announced.
In June, a settlement ending the sale of opioids by Johnson & Johnson nationwide that will bring in $ 230 million in New York City alone was announced. The deals with Johnson & Johnson, McKesson, Cardinal Health and Amerisource Bergen have an aggregate value of around $ 26 billion.
The cases against Mallinckrodt and Rochester Drug Cooperative are now proceeding separately in the United States bankruptcy court.
The trial against the two remaining defendants – Teva Pharmaceuticals USA and Allergan Finance – is currently ongoing and is continuing in state court.
Under the new law establishing the Opioid Settlement Fund, all funds raised by the state from opioid settlements or court victories will be allocated specifically to reduction efforts in communities devastated by the opioid epidemic and will not go to the general state fund.
Every region, and especially every county in the state, will receive millions of dollars for prevention, treatment and recovery programs to fight the opioid crisis.
The numbers below represent the minimum and maximum amounts each region can receive from settlements with Johnson & Johnson, McKesson, Cardinal Health, Amerisource Bergen, and Endo. The more locations across the state that accept the terms of these various regulations, the more each location is eligible to receive. The figures below do not include payments from Purdue Pharma or the Sackler family, as the regional breakdown for these settlements is still being finalized. These funds, along with any funds from future or pending litigation, would be in addition to the funds announced by James today.